-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Risvodetinib Succinate in Dysphagia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Risvodetinib Succinate in Dysphagia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Risvodetinib Succinate in Dysphagia Drug Details: Risvodetinib succinate (Ikt-148009) is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Risvodetinib Succinate in Parkinson’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Risvodetinib Succinate in Parkinson's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Risvodetinib Succinate in Parkinson's Disease Drug Details: Risvodetinib succinate (Ikt-148009) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FB-418 in Parkinson’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FB-418 in Parkinson's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FB-418 in Parkinson's Disease Drug Details: FB-418 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FB-418 in Amyotrophic Lateral Sclerosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FB-418 in Amyotrophic Lateral Sclerosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FB-418 in Amyotrophic Lateral Sclerosis Drug Details: FB-418 is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Imatinib in Pulmonary Arterial Hypertension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Imatinib in Pulmonary Arterial Hypertension report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Imatinib in Pulmonary Arterial Hypertension Drug Details: Imatinib (AER-901) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dasatinib in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dasatinib in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dasatinib in Chronic Myelocytic Leukemia (CML, Chronic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ELVN-001 in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ELVN-001 in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ELVN-001 in Chronic Myelocytic Leukemia (CML, Chronic...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Saracatinib Difumarate in Psychosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Saracatinib Difumarate in Psychosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Saracatinib Difumarate in Psychosis Drug Details: Saracatinib difumarate (AZD-0530) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Saracatinib Difumarate in Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Saracatinib Difumarate in Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Saracatinib Difumarate in Fibrodysplasia Ossificans Progressiva (Myositis...
-
Company Insights
Innovation and Patenting activity of ABL Bio Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of ABL Bio Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...